Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011, Article ID 419524, 13 pages
http://dx.doi.org/10.4061/2011/419524
Review Article

Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

1Specialty School of Nephrology, DMCO, University of Milano Via di Rudini 8, 20142 Milano, Italy
2Nephrology and Dialysis Unit, San Carlo Borromeo Hospital, Via Pio II 3, 20153 Milano, Italy

Received 13 March 2011; Accepted 14 March 2011

Academic Editor: Biagio Raffaele Di Iorio

Copyright © 2011 Luciana Gravellone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. J. Sarnak, B. E. Coronado, T. Greene et al., “Cardiovascular disease risk factors in chronic renal insufficiency,” Clinical Nephrology, vol. 57, no. 5, pp. 327–335, 2002. View at Google Scholar · View at Scopus
  3. R. Vanholder, Z. Massy, A. Argiles et al., “Chronic kidney disease as cause of cardiovascular morbidity and mortality,” Nephrology Dialysis Transplantation, vol. 20, pp. 1048–1056, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. G. A. Block, T. E. Hulbert-Shearon, N. W. Levin, and F. K. Port, “Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study,” American Journal of Kidney Diseases, vol. 31, no. 4, pp. 607–617, 1998. View at Google Scholar · View at Scopus
  5. M. Teng, M. Wolf, M. N. Ofsthun et al., “Activated injectable vitamin D and hemodialysis survival: a historical cohort study,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1115–1125, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. F. Llach and F. Velasquez Forero, “Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects,” American Journal of Kidney Diseases, vol. 38, no. 5, supplement 5, pp. S20–S33, 2001. View at Google Scholar · View at Scopus
  7. G. A. Block, P. S. Klassen, J. M. Lazarus, N. Ofsthun, E. G. Lowrie, and G. M. Chertow, “Mineral metabolism, mortality, and morbidity in maintenance hemodialysis,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2208–2218, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. D. L. Andress, “Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation,” Kidney International, vol. 69, no. 1, pp. 33–43, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. J. Lund, D. L. Andress, M. Amdahl, L. A. Williams, and R. P. Heaney, “Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients,” American Journal of Nephrology, vol. 31, no. 2, pp. 165–170, 2010. View at Publisher · View at Google Scholar · View at PubMed
  10. L. A. Greenbaum, N. Benador, S. L. Goldstein et al., “Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis,” American Journal of Nephrology, vol. 28, no. 1, pp. 97–106, 2008. View at Google Scholar
  11. D. Coyne, M. Acharya, P. Qiu et al., “Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD,” American Journal of Kidney Diseases, vol. 47, no. 2, pp. 263–276, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. K. J. Martin, E. A. González, M. Gellens, L. L. Hamm, H. Abboud, and J. Lindberg, “19-nor-1-α-25-dihydroxyvitamin D (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis,” Journal of the American Society of Nephrology, vol. 9, no. 8, pp. 1427–1432, 1998. View at Google Scholar · View at Scopus
  13. J. Lindberg, K. J. Martin, E. A. González, S. R. Acchiardo, J. R. Valdin, and C. Soltanek, “A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease,” Clinical Nephrology, vol. 56, no. 4, pp. 315–323, 2001. View at Google Scholar · View at Scopus
  14. S. M. Sprague, F. Llach, M. Amdahl, C. Taccetta, and D. Batlle, “Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism,” Kidney International, vol. 63, no. 4, pp. 1483–1490, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. N. Mittman, R. Khana, S. Rani et al., “Comparison of paricalcitol and calcitriol therapy for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis,” in Proceedings of the American Society of Nephrology Renal Week Conference, St. Louis, Mo, USA, October-November 2004.
  16. D. W. Coyne, M. Grieff, S. N. Ahya, K. Giles, K. Norwood, and E. Slatopolsky, “Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D and 1,25-dihydroxy-vitamin D on serum calcium and phosphorus in hemodialysis patients,” American Journal of Kidney Diseases, vol. 40, no. 6, pp. 1283–1288, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. R. J. Lund, D. L. Andress, M. Amdahl, L. A. Williams, and R. P. Heaney, “Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients,” American Journal of Nephrology, vol. 31, no. 2, pp. 165–170, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. N. Mittman, B. Desiraju, K. B. Meyer, J. Chattopadhyay, and M. M. Avram, “Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study,” Kidney International Supplement, no. 117, pp. S33–S36, 2010. View at Google Scholar
  19. H. E. Joist, S. N. Ahya, K. Giles, K. Norwood, E. Slatopolsky, and D. W. Coyne, “Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients,” Clinical Nephrology, vol. 65, no. 5, pp. 335–341, 2006. View at Google Scholar · View at Scopus
  20. J. M. Frazão, L. Elangovan, H. M. Maung et al., “Intermittent doxercalciferol (1α-hydroxyvitamin d) therapy for secondary hyperparathyroidism,” American Journal of Kidney Diseases, vol. 36, no. 3, pp. 550–561, 2000. View at Google Scholar · View at Scopus
  21. J. W. Coburn, H. M. Maung, L. Elangovan et al., “Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4,” American Journal of Kidney Diseases, vol. 43, no. 5, pp. 877–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. L. Zisman, W. Ghantous, P. Schinleber, L. Roberts, and S. M. Sprague, “Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol,” American Journal of Nephrology, vol. 25, no. 6, pp. 591–595, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. Hayashi, Y. Tsuchiya, Y. Itaya et al., “Comparison of the effects calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized propective multicenter trial,” Nephrology Dialysis Transplantation, vol. 19, no. 8, pp. 2067–2073, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. K. Shiizaki, S. Negi, I. Hatamura et al., “Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 97–108, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. J. Kazama, H. Maruyama, I. Narita, and F. Gejyo, “Maxacalcitol is a possible less phosphatemic vitamin D analog,” Therapeutic Apheresis and Dialysis, vol. 9, no. 4, pp. 352–354, 2005. View at Google Scholar · View at Scopus
  26. Y. Oyama, J. J. Kazama, K. Omori et al., “Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism,” Clinical and Experimental Nephrology, vol. 9, no. 2, pp. 142–147, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. S. Okuno, E. Ishimura, K. Kitatani et al., “Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secodary hyperparathyroidism,” Nephrology Dialysis Transplantation, vol. 18, no. 12, pp. 2613–2621, 2003. View at Publisher · View at Google Scholar
  28. K. Shiizaki, I. Hatamura, S. Negi et al., “Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia,” Kidney International, vol. 64, no. 3, pp. 992–1003, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. T. Akizawa and K. Kurokawa, “Long-term clinical effect of maxacalcitol on hemodialysis patients with secondary hyperparathyroidism,” Clinical Calcium, vol. 12, no. 6, pp. 781–788, 2002. View at Google Scholar
  30. A. Saito, Y. Matsumoto, Y. Oyama, M. Asaka, and H. Yokoyama, “Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism,” Therapeutic Apheresis and Dialysis, vol. 14, no. 1, pp. 98–103, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. E. Slatopolsky, M. Cozzolino, Y. Lu et al., “Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia,” Kidney International, vol. 63, no. 6, pp. 2020–2027, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. J. Kazama, K. Omori, N. Takahashi et al., “Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism,” Clinical Nephrology, vol. 64, no. 1, pp. 64–68, 2005. View at Google Scholar · View at Scopus
  33. D. G. Dobrez, A. Mathes, M. Amdahl, S. E. Marx, J. Z. Melnick, and S. M. Sprague, “Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings,” Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1174–1181, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. G. Vervloet and J. W.R. Twisk, “Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 703–706, 2009. View at Publisher · View at Google Scholar · View at PubMed
  35. M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J. M. Lazarus, and R. Thadhani, “Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy,” New England Journal of Medicine, vol. 349, no. 5, pp. 446–456, 2003. View at Publisher · View at Google Scholar · View at PubMed
  36. F. Tentori, W. C. Hunt, C. A. Stidley et al., “Mortality risk among hemodialysis patients receiving different vitamin D analogs,” Kidney International, vol. 70, no. 10, pp. 1858–1865, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. N. Bodyak, J. C. Ayus, S. Achinger et al., “Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 43, pp. 16810–16815, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. W. Xiang, J. Kong, S. Chen et al., “Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems,” American Journal of Physiology, vol. 288, no. 1, pp. E125–E132, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. C. Zhou, F. Lu, K. Cao, DI. Xu, D. Goltzman, and D. Miao, “Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice,” Kidney International, vol. 74, no. 2, pp. 170–179, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. The PRIMO Study—Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Chronic Kidney Disease Stage 3 and 4 (ongoing), http://clinicaltrials.gov/ct2/show/NCT00497146.
  41. M. Mizobuchi, J. L. Finch, D. R. Martin, and E. Slatopolsky, “Differential effects of vitamin D receptor activators on vascular calcification in uremic rats,” Kidney International, vol. 72, no. 6, pp. 709–715, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. K. Husain, E. Suarez, A. Isidro, and L. Ferder, “Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas,” American Journal of Nephrology, vol. 32, no. 4, pp. 296–304, 2010. View at Publisher · View at Google Scholar · View at PubMed
  43. R. Agarwal, M. Acharya, J. Tian et al., “Antiproteinuric effect of oral paricalcitol in chronic kidney disease,” Kidney International, vol. 68, no. 6, pp. 2823–2828, 2005. View at Publisher · View at Google Scholar · View at PubMed
  44. D. De Zeeuw, R. Agarwal, M. Amdahl et al., “Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial,” The Lancet, vol. 376, no. 9752, pp. 1543–1551, 2010. View at Publisher · View at Google Scholar
  45. S. Fishbane, H. Chittineni, M. Packman, P. Dutka, N. Ali, and N. Durie, “Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial,” American Journal of Kidney Diseases, vol. 54, no. 4, pp. 647–652, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. Z. Zhang, Y. Zhang, G. Ning, D. K. Deb, J. Kong, and C. L. Yan, “Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 41, pp. 15896–15901, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. M. Freundlich, Y. Quiroz, Z. Zhang et al., “Suppression of renin-angiotensin gene expression in the kidney by paricalcitol,” Kidney International, vol. 74, no. 11, pp. 1394–1402, 2008. View at Publisher · View at Google Scholar · View at PubMed
  48. X. Tan, X. Wen, and Y. Liu, “Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-κB signaling,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1741–1752, 2008. View at Publisher · View at Google Scholar · View at PubMed
  49. X. X. Wang, T. Jiang, Y. Shen et al., “Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism,” American Journal of Physiology, vol. 300, no. 3, pp. F801–F810, 2011. View at Google Scholar
  50. P. Alborzi, N. A. Patel, C. Peterson et al., “Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial,” Hypertension, vol. 52, no. 2, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. T. Eleftheriadis, G. Antoniadi, V. Liakopoulos, C. Kartsios, I. Stefanidis, and G. Galaktidou, “Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells,” International Urology and Nephrology, vol. 42, no. 1, pp. 181–185, 2010. View at Publisher · View at Google Scholar · View at PubMed
  52. J. R. Wu-Wong, W. Noonan, M. Nakane et al., “Vitamin D receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats,” International Journal of Endocrinology, vol. 2010, Article ID 625852, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. E. Karavalakis, A. Eräranta, T. I. Vehmas et al., “Paricalcitol treatment and arterial tone in experimental renal insufficiency,” Nephron Experimental Nephrology, vol. 109, no. 3, pp. e84–e93, 2008. View at Publisher · View at Google Scholar · View at PubMed
  54. A. Levin and Y. C. Li, “Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?” Kidney International, vol. 68, no. 5, pp. 1973–1981, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. R. Ebert, N. Schütze, J. Adamski, and F. Jakob, “Vitamin D signaling is modulated on multiple levels in health and disease,” Molecular and Cellular Endocrinology, vol. 248, no. 1-2, pp. 149–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
  56. J. R. Wu-Wong, “Potential for vitamin D receptor agonists in the treatment of cardiovascular disease,” British Journal of Pharmacology, vol. 158, no. 2, pp. 395–412, 2009. View at Publisher · View at Google Scholar · View at PubMed